Invasive coronary angiography (ICA) is the gold standard in the diagnosis of coronary artery disease (CAD). Being invasive, it carries rare but serious risks including myocardial infarction, stroke, major bleeding, and death. A large proportion of elective outpatients undergoing ICA have nonobstructive CAD, highlighting the suboptimal use of this test. Coronary computed tomographic angiography (CCTA) is a noninvasive option that provides similar information with less risk and is recommended as a first-line test for patients with low-to-intermediate risk of CAD. Leveraging artificial intelligence (AI) to appropriately direct patients to ICA or CCTA based on the predicted probability of disease may improve the efficiency and safety of diagnostic pathways. he CarDIA-AI (Coronary computed tomographic angiography to optimize the Diagnostic yield of Invasive Angiography for low-risk patients screened with Artificial Intelligence) study aims to evaluate whether AI-based risk assessment for obstructive CAD implemented within a centralized triage process can optimize the use of ICA in outpatients referred for nonurgent ICA. CarDIA-AI is a pragmatic, open-label, superior randomized controlled trial involving 2 Canadian cardiac centers. A total of 252 adults referred for elective outpatient ICA will be randomized 1:1 to usual care (directly proceeding to ICA) or to triage using an AI-based decision support tool. The AI-based decision support tool was developed using referral information from over 37,000 patients and uses a light gradient boosting machine model to predict the probability of obstructive CAD based on 42 clinically relevant predictors, including patient referral information, demographic characteristics, risk factors, and medical history. Participants in the intervention arm will have their ICA referral forms and medical charts reviewed, and select details entered into the decision support tool, which recommends CCTA or ICA based on the patient's predicted probability of obstructive CAD. All patients will receive the selected imaging modality within 6 weeks of referral and will be subsequently followed for 90 days. The primary outcome is the proportion of normal or nonobstructive CAD diagnosed via ICA and will be assessed using a 2-sided z test to compare the patients referred for cardiac investigation with normal or nonobstructive CAD diagnosed through ICA between the intervention and control groups. Secondary outcomes include the number of angiograms avoided and the diagnostic yield of ICA. Recruitment began on January 9, 2025, and is expected to conclude in mid to late 2025. As of April 14, 2025, we have enrolled 81 participants. Data analysis will begin once data collection is completed. We expect to submit the results for publication in 2026. CarDIA-AI will be the first randomized controlled trial using AI to optimize patient selection for CCTA versus ICA, potentially improving diagnostic efficiency, avoiding unnecessary complications of ICA, and improving health care resource usage. ClinicalTrials.gov NCT06648239; https://clinicaltrials.gov/study/NCT06648239/. DERR1-10.2196/71726.

Dynamic FDG PET imaging study of n = 52 rats including 26 control Wistar-Kyoto (WKY) rats and 26 experimental spontaneously hypertensive rats (SHR) were performed using a Siemens microPET and Albira trimodal scanner longitudinally at 1, 2, 3, 5, 9, 12 and 18 months of age. A 15-parameter dual output model correcting for spill over contamination and partial volume effects with peak fitting cost functions was developed for simultaneous estimation of model corrected blood input function (MCIF) and kinetic rate constants for dynamic FDG PET images of rat heart in vivo. Major drawbacks of this model are its dependence on manual annotations for the Image Derived Input Function (IDIF) and manual determination of crucial model parameters to compute MCIF. To overcome these limitations, we performed semi-automated segmentation and then formulated a Long-Short-Term Memory (LSTM) cell network to train and predict MCIF in test data using a concatenation of IDIFs and myocardial inputs and compared them with reference-modeled MCIF. Thresholding along 2D plane slices with two thresholds, with T1 representing high-intensity myocardium, and T2 representing lower-intensity rings, was used to segment the area of the LV blood pool. The resultant IDIF and myocardial TACs were used to compute the corresponding reference (model) MCIF for all data sets. The segmented IDIF and the myocardium formed the input for the LSTM network. A k-fold cross validation structure with a 33:8:11 split and 5 folds was utilized to create the model and evaluate the performance of the LSTM network for all datasets. To overcome the sparseness of data as time steps increase, midpoint interpolation was utilized to increase the density of datapoints beyond time = 10 minutes. The model utilizing midpoint interpolation was able to achieve a 56.4% improvement over previous Mean Squared Error (MSE).

Magnetic Resonance Imaging (MRI) is highly susceptible to motion artifacts due to the extended acquisition times required for k-space sampling. These artifacts can compromise diagnostic utility, particularly for dynamic imaging. We propose a novel alternating minimization framework that leverages a bespoke diffusion model to jointly reconstruct and correct non-rigid motion-corrupted k-space data. The diffusion model uses a coarse-to-fine denoising strategy to capture large overall motion and reconstruct the lower frequencies of the image first, providing a better inductive bias for motion estimation than that of standard diffusion models. We demonstrate the performance of our approach on both real-world cine cardiac MRI datasets and complex simulated rigid and non-rigid deformations, even when each motion state is undersampled by a factor of 64x. Additionally, our method is agnostic to sampling patterns, anatomical variations, and MRI scanning protocols, as long as some low frequency components are sampled during each motion state.

To develop an interpretable machine learning (ML) model based on cardiac magnetic resonance (CMR) multimodal parameters and clinical data to discriminate Takotsubo syndrome (TTS), acute myocardial infarction (AMI), and acute myocarditis (AM), and to further assess the diagnostic value of right ventricular (RV) strain in TTS. This study analyzed CMR and clinical data of 130 patients from three centers. Key features were selected using least absolute shrinkage and selection operator regression and random forest. Data were split into a training cohort and an internal testing cohort (ITC) in the ratio 7:3, with overfitting avoided using leave-one-out cross-validation and bootstrap methods. Nine ML models were evaluated using standard performance metrics, with Shapley additive explanations (SHAP) analysis used for model interpretation. A total of 11 key features were identified. The extreme gradient boosting model showed the best performance, with an area under the curve (AUC) value of 0.94 (95% CI: 0.85-0.97) in the ITC. Right ventricular basal circumferential strain (RVCS-basal) was the most important feature for identifying TTS. Its absolute value was significantly higher in TTS patients than in AMI and AM patients (-9.93%, -5.21%, and -6.18%, respectively, p < 0.001), with values above -6.55% contributing to a diagnosis of TTS. This study developed an interpretable ternary classification ML model for identifying TTS and used SHAP analysis to elucidate the significant value of RVCS-basal in TTS diagnosis. An online calculator (https://lsszxyy.shinyapps.io/XGboost/) based on this model was developed to provide immediate decision support for clinical use.

PurposeTo develop a segmentation and quality control pipeline for short-axis cardiac magnetic resonance (CMR) cine images from the prospective, multi-center German National Cohort (NAKO). Materials and MethodsA deep learning model for semantic segmentation, based on the nnU-Net architecture, was applied to full-cycle short-axis cine images from 29,908 baseline participants. The primary objective was to determine data on structure and function for both ventricles (LV, RV), including end diastolic volumes (EDV), end systolic volumes (ESV), and LV myocardial mass. Quality control measures included a visual assessment of outliers in morphofunctional parameters, inter- and intra-ventricular phase differences, and LV time-volume curves (TVC). These were adjudicated using a five-point rating scale, ranging from five (excellent) to one (non-diagnostic), with ratings of three or lower subject to exclusion. The predictive value of outlier criteria for inclusion and exclusion was analyzed using receiver operating characteristics. ResultsThe segmentation model generated complete data for 29,609 participants (incomplete in 1.0%) and 5,082 cases (17.0 %) were visually assessed. Quality assurance yielded a sample of 26,899 participants with excellent or good quality (89.9%; exclusion of 1,875 participants due to image quality issues and 835 cases due to segmentation quality issues). TVC was the strongest single discriminator between included and excluded participants (AUC: 0.684). Of the two-category combinations, the pairing of TVC and phases provided the greatest improvement over TVC alone (AUC difference: 0.044; p<0.001). The best performance was observed when all three categories were combined (AUC: 0.748). Extending the quality-controlled sample to include acceptable quality ratings, a total of 28,413 (95.0%) participants were available. ConclusionThe implemented pipeline facilitated the automated segmentation of an extensive CMR dataset, integrating quality control measures. This methodology ensures that ensuing quantitative analyses are conducted with a diminished risk of bias.

Low-dose colchicine (0.5 mg once daily) reduces the risk of major cardiovascular events in coronary disease, but its mechanism of action is not yet fully understood. We investigated whether low-dose colchicine is associated with changes in pericoronary inflammation and plaque composition in patients with chronic coronary disease. We performed a cross-sectional, nationwide, subanalysis of the Low-Dose Colchicine 2 Trial (LoDoCo2, n=5522). CT angiography studies were performed in 151 participants randomised to colchicine or placebo coronary after a median treatment duration of 28.2 months. Pericoronary adipose tissue (PCAT) attenuation measurements around proximal coronary artery segments and quantitative plaque analysis for the entire coronary tree were performed using artificial intelligence-enabled plaque analysis software. Median PCAT attenuation was not significantly different between the two groups (-79.5 Hounsfield units (HU) for colchicine versus -78.7 HU for placebo, p=0.236). Participants assigned to colchicine had a higher volume (169.6 mm³ vs 113.1 mm³, p=0.041) and burden (9.6% vs 7.0%, p=0.035) of calcified plaque, and higher volume of dense calcified plaque (192.8 mm³ vs 144.3 mm³, p=0.048) compared with placebo, independent of statin therapy. Colchicine treatment was associated with a lower burden of low-attenuation plaque in participants on a low-intensity statin, but not in those on a high-intensity statin (p_interaction=0.037). Pericoronary inflammation did not differ among participants who received low-dose colchicine compared with placebo. Low-dose colchicine was associated with a higher volume of calcified plaque, particularly dense calcified plaque, which is considered a feature of plaque stability.

AimsAortic stenosis (AS) is a progressive disease requiring timely monitoring and intervention. While transthoracic echocardiography (TTE) remains the diagnostic standard, deep learning (DL)-based approaches offer potential for improved disease tracking. This study examined the longitudinal changes in a previously developed DL-derived index for AS continuum (DLi-ASc) and assessed its value in predicting progression to severe AS. Methods and ResultsWe retrospectively analysed 2,373 patients a(7,371 TTEs) from two tertiary hospitals. DLi-ASc (scaled 0-100), derived from parasternal long- and/or short-axis views, was tracked longitudinally. DLi-ASc increased in parallel with worsening AS stages (p for trend <0.001) and showed strong correlations with AV maximal velocity (Vmax) (Pearson correlation coefficients [PCC] = 0.69, p<0.001) and mean pressure gradient (mPG) (PCC = 0.66, p<0.001). Higher baseline DLi-ASc was associated with a faster AS progression rate (p for trend <0.001). Additionally, the annualised change in DLi-ASc, estimated using linear mixed-effect models, correlated strongly with the annualised progression of AV Vmax (PCC = 0.71, p<0.001) and mPG (PCC = 0.68, p<0.001). In Fine-Gray competing risk models, baseline DLi-ASc independently predicted progression to severe AS, even after adjustment for AV Vmax or mPG (hazard ratio per 10-point increase = 2.38 and 2.80, respectively) ConclusionDLi-ASc increased in parallel with AS progression and independently predicted severe AS progression. These findings support its role as a non-invasive imaging-based digital marker for longitudinal AS monitoring and risk stratification.

The application of AI for predicting critical heart failure endpoints using echocardiography is a promising avenue to improve patient care and treatment planning. However, fully supervised training of deep learning models in medical imaging requires a substantial amount of labelled data, posing significant challenges due to the need for skilled medical professionals to annotate image sequences. Our study addresses this limitation by exploring the potential of self-supervised learning, emphasising interpretability, robustness, and safety as crucial factors in cardiac imaging analysis. We leverage self-supervised learning on a large unlabelled dataset, facilitating the discovery of features applicable to a various downstream tasks. The backbone model not only generates informative features for training smaller models using simple techniques but also produces features that are interpretable by humans. The study employs a modified Self-supervised Transformer with Energy-based Graph Optimisation (STEGO) network on top of self-DIstillation with NO labels (DINO) as a backbone model, pre-trained on diverse medical and non-medical data. This approach facilitates the generation of self-segmented outputs, termed "parcels", which identify distinct anatomical sub-regions of the heart. Our findings highlight the robustness of these self-learned parcels across diverse patient profiles and phases of the cardiac cycle phases. Moreover, these parcels offer high interpretability and effectively encapsulate clinically relevant cardiac substructures. We conduct a comprehensive evaluation of the proposed self-supervised approach on publicly available datasets, demonstrating its adaptability to a wide range of requirements. Our results underscore the potential of self-supervised learning to address labelled data scarcity in medical imaging, offering a path to improve cardiac imaging analysis and enhance the efficiency and interpretability of diagnostic procedures, thus positively impacting patient care and clinical decision-making.

The Segment Anything Model (SAM) was fine-tuned on the EchoNet-Dynamic dataset and evaluated on external transthoracic echocardiography (TTE) and Point-of-Care Ultrasound (POCUS) datasets from CAMUS (University Hospital of St Etienne) and Mayo Clinic (99 patients: 58 TTE, 41 POCUS). Fine-tuned SAM was superior or comparable to MedSAM. The fine-tuned SAM also outperformed EchoNet and U-Net models, demonstrating strong generalization, especially on apical 2-chamber (A2C) images (fine-tuned SAM vs. EchoNet: CAMUS-A2C: DSC 0.891 {+/-} 0.040 vs. 0.752 {+/-} 0.196, p<0.0001) and POCUS (DSC 0.857 {+/-} 0.047 vs. 0.667 {+/-} 0.279, p<0.0001). Additionally, SAM-enhanced workflow reduced annotation time by 50% (11.6 {+/-} 4.5 sec vs. 5.7 {+/-} 1.7 sec, p<0.0001) while maintaining segmentation quality. We demonstrated an effective strategy for fine-tuning a vision foundation model for enhancing clinical workflow efficiency and supporting human-AI collaboration.